Metro-Minnesota Community Clinical Oncology Program

大都会-明尼苏达州社区临床肿瘤学计划(MMCCOP)代表了由九家医院组成的联盟， 通过NCI资助的社区医院肿瘤学计划(CHOP)和运营CCOP，已经开发出一种共同的 癌症患者的管理方法，并建立了识别、进入和跟踪患者的机制 关于治疗和癌症预防和控制方案。该联盟拥有全社会范围的计算机化数据管理 能够进行前瞻性数据收集的系统。该社区提供PPO、HMO和商业医疗计划，所有这些 在这九家财团医院中有代表。九家医院加在一起，平均有9700个新的分析 每年的癌症患者人数。100名核心和即将上任的新调查人员，代表医学和放射肿瘤学、血液学、 泌尿科、妇科肿瘤科、神经科、耳鼻咽喉科、全科医生、普通外科医生和专科外科医生广泛合作。 关于癌症方案制定和方案制定的现行方案的结构和操作。在最近的 NCI资助资助年度(6/03-5/04)，880名患者/参与者(192.3个治疗学分，299.6个癌症控制学分)累积到 NCI批准的治疗和癌症预防和控制研究。MMCCOP打算维持一个区域范围的社区 和医院联盟，为社区提供癌症预防、控制和治疗方面的最新进展。 这将通过将社区合作伙伴关系进一步扩大到现有的外展社区来实现；与医院合作， 基金会、保险公司和综合服务网络(ISNS)为参与 临床试验；增加初级保健医生的参与；提供专业知识、资源和庞大的人口基础 通过与NCI、CTSU、ECOG、GOG、 MD Anderson、NSABP、RTOG、URCC和与NCCTG的试点项目；改进和扩展当前MMCCOP数据 管理和沟通系统，以增加调查人员参与应计方案的数量和水平 业务和研究基地活动；实施新战略，改善少数群体和服务不足的人的机会和参与 并提高专业人士和社会各界对CCOP和癌症临床试验益处的认识。基于 过去的经验，癌症控制和预防试验的可用性，多个研究基地和成功的癌症控制 实施模式，MMCCOP调查人员打算注册1,040人(581.6学分/413.5新的168.1后续行动) 患者/参与者在第一年接受NCI批准的癌症治疗和控制研究，目标是继续 超过NCI对这两种类型研究的要求。当时的评审员认为之前的MMCCOP申请是 “过于乐观”，但被超越了。这笔拨款第一年的目标又是乐观的，但现实地考虑到了专业知识 在这一群体中，可用的方案、已建立的系统以及医生和医院的大力支持。

The Metro-Minnesota Community Clinical Oncology Program(MMCCOP) represents a consortium of nine hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operational CCOP, has developed acommon approach to the management of cancer patients and has an established mechanism for identifying, entering and following patients on treatment and cancer prevention and control protocols. The consortium has a community-wide computerized data management system capable of prospective data collection. The community offers PPOs, HMOs and commercial healthcare programs, all of which are represented among these nine consortium hospitals. Together, the nine hospitals see an averageof 9700 new analytic cancer patients per year. The 100 core and pending new investigators, representing medical and radiation oncology, hematology, urology, gynecologic oncology, neurology, ENT, family practice, general and specialty surgeons, have worked extensively together on cancer program development and protocol development of the current program structure and operation. During the most recent NCI-funded grant year (6/03-5/04), 880 patients/participants (192.3 treatmentcredits+299.6 cancer control credits) were accrued to NCI-approved treatment and cancer prevention and control studies. The MMCCOP intends to sustain a region wide community and hospital consortium, which provides the community with the most recent advances in cancer prevention, control and treatment. This will be accomplished through further expansion of the CCOP into established outreach communities; work withhospitals, foundations, insurers and Integrated Service Networks (ISNs) to develop funding and reimbursement support for participation in clinical trials; increased involvement of primary care physicians; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, CTSU, ECOG, GOG, MD Anderson, NSABP, RTOG, URCC and pilot project with the NCCTG; improve and expand the current MMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities; implement new strategies to improve access and participation of minority and underserved groups; and increase the professionaland lay community awareness of the CCOP and benefits of clinical cancer trials. Based upon past experience, the availability of cancer control and prevention trials, multiple research bases and successful cancer control implementation models, MMCCOP investigators intend to enroll 1040 (581.6 credits/413.5 new + 168.1 follow-up) patients/participants onto NCI-approved cancer treatment and control studies during the first year, with the goal of continually exceeding the NCI requirements for both types of studies. Prior MMCCOP applications were viewed by reviewers at that time as "overly optimistic",but were exceeded. The goal for the first year of this grant is again optimistic, but realisticgiventhe expertise of the group, available protocols, the established systems and strong support of the physiciansandhospitals.